ATRECA INC - A (BCEL) Stock Price & Overview
NASDAQ:BCEL • US04965G1094
Current stock price
The current stock price of BCEL is 0.15 USD. Today BCEL is down by -11.76%. In the past month the price decreased by -51.61%. In the past year, price decreased by -87.8%.
BCEL Key Statistics
- Market Cap
- 5.943M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.95
- Dividend Yield
- N/A
BCEL Stock Performance
BCEL Stock Chart
BCEL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCEL. When comparing the yearly performance of all stocks, BCEL is a bad performer in the overall market: 97.03% of all stocks are doing better.
BCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCEL. While BCEL seems to be doing ok healthwise, there are quite some concerns on its profitability.
BCEL Earnings
BCEL Forecast & Estimates
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15.
BCEL Groups
Sector & Classification
BCEL Financial Highlights
Over the last trailing twelve months BCEL reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS increased by 29.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -371.75% | ||
| ROE | -905.28% | ||
| Debt/Equity | 0 |
BCEL Ownership
BCEL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.92 | 388.432B | ||
| AMGN | AMGEN INC | 16.05 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.04 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.19 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.74 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.4 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 341.66 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCEL
Company Profile
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Company Info
IPO: 2019-06-20
ATRECA INC - A
835 Industrial Road,, 75 Shoreway Road, Suite C
San Carlos CALIFORNIA 94063 US
CEO: John A. Orwin
Employees: 90
Phone: 16505952595
ATRECA INC - A / BCEL FAQ
What does BCEL do?
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
What is the stock price of ATRECA INC - A today?
The current stock price of BCEL is 0.15 USD. The price decreased by -11.76% in the last trading session.
What is the dividend status of ATRECA INC - A?
BCEL does not pay a dividend.
How is the ChartMill rating for ATRECA INC - A?
BCEL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BCEL stock to perform?
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15.
What is ATRECA INC - A worth?
ATRECA INC - A (BCEL) has a market capitalization of 5.94M USD. This makes BCEL a Nano Cap stock.